Abdominal and Pelvic Vascular Trauma

64.1REBOA is a selective bridge

The unstable patient with abdominal or pelvic vascular trauma is not asking whether an aortic balloon can raise the blood pressure. The operative question is whether temporary hemorrhage control can be created quickly enough to reach definitive control without adding avoidable ischemic, access-site, or decision-delay harm. Contemporary REBOA guidance therefore fits best as a restrictive bridge-to-control strategy: it may be appropriate in selected exsanguinating patients when the suspected bleeding territory is anatomically compatible with aortic occlusion, when the team can obtain safe arterial access, and when laparotomy, pelvic hemorrhage control, angioembolization, open vascular repair, endovascular repair, or transfer is already being executed rather than merely contemplated. The EAST practice management guideline and the Western Trauma Association critical-decision algorithm support this selective bridge framing rather than treating REBOA as general resuscitation therapy REBOA 2025 · Western Trauma Association 2022.

The first bedside distinction is compressible versus non-compressible bleeding. External hemorrhage, junctional bleeding that can be temporized by direct pressure or packing, and extremity hemorrhage need rapid local control; an aortic balloon is not a substitute for stopping visible bleeding. REBOA enters the conversation when the physiology is that of non-compressible torso or pelvic hemorrhage and the team believes temporary aortic occlusion will buy time for a defined next maneuver. That next maneuver must be named before the balloon is inflated. In abdominal vascular trauma it may be immediate laparotomy with proximal control, rapid packing followed by vascular exposure, shunting, ligation, or repair. In pelvic fracture hemorrhage it may be pelvic binder placement, preperitoneal packing, external fixation, angioembolization, or a hybrid sequence. In a center without immediate definitive capability, the endpoint may be controlled transfer, but only if temporary occlusion can be maintained safely and the receiving pathway is real. The ESVS vascular trauma guideline and the AAST/ACS-COT damage-control resuscitation protocol both support making the sequence from resuscitation to operative, endovascular, or hybrid source control explicit ESVS 2025 · AAST ACS-COT clinical 2024.

Access and balloon management are part of the indication, not technical afterthoughts. A patient who is peri-arrest, coagulopathic, vasoconstricted, or anatomically difficult may be exactly the patient in whom arterial access consumes time, causes injury, or distracts senior operators from laparotomy. Conversely, a team that has rehearsed ultrasound-guided common femoral access, wire control, balloon selection, zone confirmation, and post-occlusion monitoring may use REBOA as a disciplined bridge while another team member opens the abdomen, stabilizes the pelvis, activates interventional radiology, or prepares the hybrid suite. The decision should be made by the trauma leader and the operator responsible for access, with explicit assignment of who is watching occlusion time, distal perfusion, balloon position, haemodynamics, and the transition to partial or complete deflation. The WTA algorithm and EAST guideline are useful because they keep the decision operational: patient selection, zone, duration, and definitive control plan dominate the risk-benefit balance REBOA 2025 · Western Trauma Association 2022.

The common error is to let a transient pressure response become the endpoint. A systolic rise after aortic occlusion can be physiologically seductive, but it does not control a bleeding iliac vein, a shattered pelvic venous plexus, a portal or hepatic venous injury, a mesenteric avulsion, or a contaminated abdominal vascular injury. It only changes upstream pressure and downstream perfusion while the team creates control. In that interval the patient may be accumulating visceral, renal, spinal, pelvic, lower-limb, and access-site risk. The safest language for the trainee is therefore procedural and conditional: REBOA may be used in selected patients as a temporary bridge when it accelerates a pre-specified control pathway; it should be abandoned or deflated when it no longer serves that pathway, when definitive control has been reached, when physiology worsens despite occlusion, or when access and positioning are consuming time better spent on laparotomy or embolization REBOA 2025 · ESVS 2025.

Damage-control resuscitation should run in parallel rather than wait for the balloon decision. Blood product resuscitation, hemorrhage protocol activation, hypothermia prevention, correction of coagulopathy, rapid imaging only when physiology permits, pelvic binder placement when indicated, airway and anesthetic coordination, and preparation for massive transfusion all remain fundamental. REBOA does not replace balanced resuscitation, and balanced resuscitation does not replace source control. The practical handoff is a spoken plan: suspected territory, temporary control method, definitive control method, location, operator, and failure trigger. A team that cannot state those elements should treat the balloon decision as incomplete, because aortic occlusion without an exit strategy is only delayed hemorrhage control.

64.2Randomized evidence sets the tone

The contemporary tone of REBOA teaching changed because randomized evidence made broad benefit language unsafe. UK-REBOA studied emergency department REBOA in trauma patients with exsanguinating hemorrhage and functions as a central boundary for the chapter: it does not support a simple claim that adding REBOA to trauma resuscitation improves outcome across the heterogeneous population of severely bleeding trauma patients Emergency Department Resuscitative 2023. For a vascular surgeon, the lesson is not that aortic occlusion has no possible role. The lesson is that the role must be tied to phenotype, timing, operator capability, and a credible route to definitive hemorrhage control. A tool that may be rational in a narrow, rehearsed, anatomically suitable pathway can still fail as an undifferentiated emergency department intervention applied across unstable trauma.

Randomized trauma trials are difficult because the intervention is inseparable from system design. REBOA is not a drug given into an otherwise unchanged pathway; it changes access priorities, staff allocation, imaging decisions, destination, anesthetic timing, and the moment at which a patient reaches laparotomy, pelvic packing, embolization, or hybrid repair. A center with immediate vascular access skill, a trauma surgeon at the bedside, rapid blood delivery, interventional radiology close to the resuscitation bay, and a hybrid operating room may experience the decision differently from a center where femoral access is slow and definitive control is remote. The UK-REBOA result therefore should not be flattened into either “never use REBOA” or “use REBOA when shocked.” It should make the team ask whether the local pathway resembles a source-control bridge or an extra procedure inserted into a failing resuscitation Emergency Department Resuscitative 2023 · AAST ACS-COT clinical 2024.

The bridge concept also explains why patient selection matters more than enthusiasm. A patient with profound pelvic fracture hemorrhage, persistent shock despite blood product resuscitation, and a clear plan for packing or embolization is different from a patient with free intraperitoneal contamination and a penetrating great-vessel injury who needs an incision now. A patient whose bleeding is above the planned occlusion territory is different from a patient whose bleeding is below it. A patient with a delayed presentation, severe metabolic failure, or prolonged arrest physiology may not gain useful time from any temporary aortic maneuver. The EAST guideline and WTA algorithm are best read in that cautious frame: REBOA is considered only when the bleeding pattern, physiology, access feasibility, and definitive pathway make temporary occlusion plausibly useful REBOA 2025 · Western Trauma Association 2022.

The trial boundary is especially important when trainees interpret a pressure response. A short-lived hemodynamic improvement can be real and still clinically misleading. It may indicate that afterload has been manipulated more than hemorrhage has been controlled. It may also worsen bleeding above the balloon, intensify proximal hypertension, or delay the definitive maneuver. The right question after inflation is therefore not “did the pressure rise?” but “what has the pressure response allowed us to complete?” If the answer is abdominal incision, pelvic packing, vascular clamp control, embolization catheter placement, endograft deployment, or safe transfer to a prepared team, the balloon has functioned as a bridge. If the answer is continued indecision in the resuscitation bay, the intervention has drifted away from its purpose.

For vascular surgeons embedded in trauma systems, the randomized evidence should sharpen rather than paralyse practice. The service should define who may place REBOA, where it is placed, how access is confirmed, who documents occlusion and deflation, how the sheath is removed or repaired, and which patients bypass the balloon and go directly to laparotomy or embolization. The AAST/ACS-COT damage-control resuscitation protocol reinforces that hemorrhage control, resuscitation, and staged reassessment must proceed together, while ESVS vascular trauma guidance keeps the vascular surgeon’s role anchored in territory-specific control rather than device-first thinking ESVS 2025 · AAST ACS-COT clinical 2024. A mature pathway can still use REBOA selectively, but it should audit each use against the promised endpoint: time gained, control achieved, complications incurred, and whether a faster non-balloon route existed.

64.3Pelvic and penetrating lanes stay separate

Pelvic fracture hemorrhage is not the same clinical problem as penetrating abdominal vascular trauma, and neither should inherit claims from the other. Pelvic bleeding is often mixed arterial, venous, and cancellous bone bleeding, compounded by pelvic volume expansion, coagulopathy, and delayed access to the bleeding surface. Its control sequence may include binder placement, transfusion, external stabilization, preperitoneal packing, angioembolization, or a hybrid combination. REBOA can reduce inflow temporarily, but it does not reduce pelvic volume, compress venous bleeding, replace packing, or embolize arterial branches. That is why pelvic-fracture REBOA evidence must be described as mixed and conditional rather than as a simple survival narrative; the systematic review and registry data admitted for this chapter support selected use with uncertainty and concerning associations rather than an unqualified benefit statement Assessing role REBOA 2026 · REBOA mortality hemorrhagic 2024 · Matched cohort study 2023.

The practical pelvic decision is sequence. If the patient is unstable and a pelvic ring injury is suspected, the binder is placed early and correctly, blood arrives early, and the team decides whether the next source-control move is packing, embolization, fixation, laparotomy for associated intraperitoneal injury, or a combined pathway. REBOA is most coherent when it shortens the interval to one of those maneuvers. It is least coherent when it substitutes for pelvic stabilization, delays transfer to the operating room or angiography suite, or is used because the team has not chosen between competing control strategies. Selection bias in registry studies is unavoidable because the sickest pelvic patients are more likely to receive aortic occlusion; at the same time, the presence of bias does not permit the opposite conclusion that the balloon is beneficial. The safe synthesis is that pelvic REBOA remains a high-acuity, system-dependent bridge whose benefit is unresolved and whose harm potential is real Assessing role REBOA 2026 · REBOA mortality hemorrhagic 2024 · Matched cohort study 2023.

Penetrating abdominal vascular trauma is a different lane because the dominant problem is often immediate surgical exposure, contamination, associated hollow-viscus injury, and proximal and distal vascular control under time pressure. Aortic occlusion may be considered in selected shocked patients, but it must not delay incision when direct control is the life-saving move. It also cannot be assumed to behave like a pelvic-fracture adjunct, because the bleeding vessel, wound tract, contamination burden, and operative route are different. Registry data in penetrating abdominal vascular injury and shocked penetrating abdominal trauma are useful as boundary evidence: they justify separating penetrating mechanisms from blunt pelvic assumptions, but they do not provide definitive causal proof that REBOA improves outcome in this lane REBOA shocked penetrating 2025 · REBOA penetrating abdominal 2025.

For the vascular surgeon, the penetrating pathway begins with exposure strategy. If the abdomen is open or opening, proximal control may be obtained with a supraceliac clamp, direct vessel control, packing, shunting, ligation, or repair depending on the injured territory and physiology. An endovascular adjunct may be useful when access is already controlled, the lesion is anatomically suitable, and the team can deploy it without compromising contamination management or operative exposure. REBOA before incision may be rational only when the patient is crashing, the suspected bleeding is below the occlusion level, access can be obtained immediately, and the balloon will accelerate the patient to laparotomy rather than keep the patient in the resuscitation bay. In contaminated penetrating trauma, durable reconstruction choices are also shaped by bowel injury, physiologic exhaustion, and the need for staged re-exploration; those decisions are not solved by aortic occlusion.

High-grade liver injury deserves its own caution because hepatic hemorrhage is neither a generic abdominal bleeding phenotype nor a pelvic analogue. Temporary aortic occlusion may alter inflow, but liver bleeding may involve complex arterial, portal venous, hepatic venous, retrohepatic caval, and parenchymal components. A single-registry signal in high-grade liver injury should therefore be treated as a boundary against overgeneralized aortic-occlusion claims rather than as a universal rule for all liver trauma REBOA high-grade liver 2025. The clinically useful point is to name the competing control options: damage-control laparotomy and packing, Pringle maneuver when appropriate, selective angioembolization, venous control strategies in expert hands, and staged reassessment. If REBOA is used in such a patient, its purpose must be narrow and temporary, and its failure trigger must be explicit.

64.4Boundary phenotypes, provenance, and reassessment

A safe abdominal and pelvic trauma pathway is built around repeated reassessment: what is bleeding, where can it be controlled fastest, what temporary maneuver is buying time, and what harm is accumulating while the team moves. After any temporary aortic occlusion, the team should reassess physiology, transfusion requirement, operative progress, distal perfusion, sheath status, metabolic burden, and the feasibility of partial or complete deflation. The end of the case is not the end of the vascular problem. The groin access site may need repair, the limb may need perfusion surveillance, the abdomen or pelvis may require staged re-exploration, and the patient may still need embolization, definitive vascular reconstruction, fasciotomy, or transfer to a higher-capability center. ESVS vascular trauma guidance and the AAST/ACS-COT damage-control resuscitation protocol both support explicit transition from resuscitation to source control and staged reassessment rather than a device-centred endpoint ESVS 2025 · AAST ACS-COT clinical 2024.

The most important boundary phenotypes should be spoken during the case. Pelvic fracture hemorrhage remains uncertain because available synthesis and registry evidence do not permit a clean survival-benefit claim for REBOA, and because pelvic control depends on stabilization, packing, embolization, and system timing as much as on inflow reduction Assessing role REBOA 2026 · REBOA mortality hemorrhagic 2024 · Matched cohort study 2023. Penetrating abdominal vascular injury should be separated from blunt pelvic trauma because mechanism, contamination, laparotomy timing, and vascular control needs differ, and available registry evidence is observational rather than definitive REBOA shocked penetrating 2025 · REBOA penetrating abdominal 2025. High-grade liver injury should be kept as a distinct cautionary phenotype when aortic occlusion is discussed, because registry evidence in that lane warns against extrapolating from other abdominal or pelvic bleeding patterns REBOA high-grade liver 2025. These distinctions keep the team from converting a temporary hemodynamic tool into a universal trauma doctrine.

EVTM has an important provenance that should be acknowledged separately from claims about present-day clinical benefit. The contemporary language of endovascular trauma management is closely associated with Tal M. Hörer and the Örebro group, the EVTM Society, and the educational and scholarly ecosystem around JEVTM. In this chapter, that lineage matters because it explains why vascular surgeons, trauma surgeons, anaesthetists, and interventional teams increasingly discuss balloons, stent grafts, hybrid access, and damage-control endovascular adjuncts as part of the same emergency pathway ESVS 2025 · EVTM Practical Aspects 2021 · Top Stent Manual 2017. That provenance should not be used as evidence that REBOA improves survival in pelvic fracture, penetrating abdominal vascular injury, or high-grade liver trauma. Current clinical claims must come from the guideline, trial, systematic review, protocol, and registry evidence cited in the relevant paragraphs.

A practical service-level pathway can be summarized as five commitments. First, the team defines candidate phenotypes before the patient arrives: suspected non-compressible pelvic or abdominal hemorrhage, failure of initial resuscitation, anatomy compatible with occlusion, and a named definitive control route. Second, the team defines exclusion and bypass logic: visible controllable hemorrhage, immediate need for laparotomy without access delay, bleeding territory unlikely to be helped by the chosen occlusion, inability to obtain safe access, or absence of an exit strategy. Third, the team rehearses access and monitoring so that the balloon does not consume the senior decision-maker. Fourth, the team documents the reason for inflation, the control maneuver it enabled, and the reason for deflation or removal. Fifth, the team reviews complications with the same seriousness as mortality: access injury, limb ischemia, renal or visceral injury, delayed laparotomy or embolization, and failure to achieve definitive control. These commitments are consistent with the restrictive bridge framing in the EAST and WTA REBOA documents and with the broader trauma source-control sequence in ESVS and AAST/ACS-COT guidance REBOA 2025 · ESVS 2025 · AAST ACS-COT clinical 2024 · Western Trauma Association 2022.

The final teaching point is humility at the bedside. REBOA can be technically impressive and physiologically dramatic, but abdominal and pelvic vascular trauma outcomes are determined by hemorrhage phenotype, speed of definitive control, blood product resuscitation, team choreography, and the complications created while buying time. UK-REBOA keeps broad claims restrained; pelvic and penetrating registry data keep mechanism-specific claims restrained; high-grade liver data keep organ-specific claims restrained Emergency Department Resuscitative 2023 · REBOA high-grade liver 2025 · REBOA penetrating abdominal 2025 · Matched cohort study 2023. The disciplined vascular trauma team can still use endovascular adjuncts, including REBOA, but only as part of a source-control plan that is already moving.